愛美客(300896.SZ):上半年淨利潤11.21億元 同比增長16.35%
格隆匯8月21日丨愛美客(300896.SZ)公佈2024年半年度報吿,報吿期營業收入16.57億元,同比增長13.53%;歸屬於上市公司股東的淨利潤11.21億元,同比增長16.35%;歸屬於上市公司股東的扣除非經常性損益的淨利潤10.89億元,同比增長16.58%;基本每股收益3.72元。
報吿期內,公司加大重大研發項目的推進力度,公司“注射用A型肉毒毒素”研發項目獲得國家藥監局藥品註冊上市許可受理通知,進入審評階段。同時,公司聯合高校院所開展產學研活動,推動科技成果轉化。公司依託博士後科研工作站與北京化工大學博士後科研流動站開展了聯合培養工作,並參與北京市自然科學基金-昌平創新聯合基金項目,在生物醫用材料等領域設置了多個重點研究專題項目和前沿項目。
報吿期內,公司溶液類與凝膠類注射產品均實現同比增長。其中,溶液類注射產品實現營業收入97,628萬元,較上年同期增長11.65%;凝膠類注射產品實現營業收入64,897萬元,較上年同期增長14.57%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.